GNH India, a company found selling COVID treatment products deemed criminally “fraudulent” by the US Food and Drug Administration, has threatened Oxebridge with “defamation proceedings” for reporting on the matter.
The FDA Warning Letter was published on the official FDA website, and the FDA has branded the Biocence products as “fraudulent.” The products in question contain eucalyptus as the main ingredient, but are marketed for the treatment of COVID-19.
Ravi Kumar, the Administrative Executive of GNH India, wrote to Oxebridge complaining of the recent reporting on the official FDA Warning Letter. Kumar doubled-down, and insisted that the products were legitimate, saying, the Biocence products are “not withdrawn the product from US market.”
Despite Kumar’s claims, the FDA does demand that Biocence products be removed from the market.
Kumar then boasted that “we have displayed both products with APPROVED LABEL claim of US FDA without adding any information related to COVID on our pages.”
This also appears to be false. The FDA Warning Letter specifically called out Biocence for its labels, insisting the claims made on them are “unlawful.” GNH nevertheless reproduces those labels entirely, including the exact language quoted in the FDA Warning Letter as being illegal.
Claims made by Biocence, deemed fraudulent by FDA, but republished on the GNH website.
To further GNH’s defense, Kumar included a June 2021 letter issued by URS Certification Ltd. announcing its recent recertification to ISO 9001:
Click to enlarge
Oxebridge has filed a report with URS, which is taking up the matter.
Curiously, a “Ravi Kumar” is listed as an ISO 9001 Lead Auditor with URS’s Indian branch, but Oxebridge has not yet been able to verify if this is a coincidence. The name is common in India. URS’s home office in the UK is looking into that issue as well.
According to papers provided by Kumar, GNH India is operated by Dr. Piyush Gupta and Shwetha Akkela.
Oxebridge has filed formal complaints against GNH with the US FDA, Indian FDA and US Federal Trade Commission.
